Buspirone augmentation of antidepressant therapy

Journal of Clinical Psychopharmacology

Volumn 18, Issue 6, 1998, Pages 465-469

  Dimitriou, Evangelos C ^a   Dimitriou, Christos E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; DEPRESSION; FEMALE; HUMAN; MALE; OUTPATIENT; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BUSPIRONE; CLOMIPRAMINE; DEPRESSION; FEMALE; HUMANS; MALE; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031760903     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199812000-00009     Document Type: Article

References (40)

1. Klein DF, Davis JM. Diagnosis and treatment of psychiatric disorders. Baltimore: Williams & Wilkins, 1969.
2. Georgotas A, McCue DS. Refractory depressions. In: Georgotas A, Cranco R, eds. Depression and mania: a comprehensive textbook. New York: Elsevier, 1988:384-91.
3. Dimitriou EC, Parashos AJ, Giouzepas JC. Buspirone vs. alprazolam: a double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms. Drug Invest 1992;4:316-21.
4. Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982;43:103-8.
5. Rickels K, Amsterdam JD, Clary C, Pussuoli G, Schweizer E. Buspirone in major depression: a controlled study. J Clin Psychiatry 1991;52:34-8.
6. Cohn JB, Bowden CL, Fisher JG, Rodos JJ. Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 1986;80:10-6.
7. Napoliello MJ. An interim multicentre report on 677 anxious geriatric outpatients treated with buspirone. Br J Clin Pract 1986; 40:71-3.
8. Fabre LF. Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 1990;51[suppl 9]:55-61.
9. Sramek JJ, Tansman M, Suri A, Hornig-Rohan M, Amsterdam JD, Stahl M, Welsler RH, Cutler NR. Efficacy of buspirone in generalised anxiety disorder with co-existing mild depressive symptoms. J Clin Psychiatry 1996;57:287-91.
10. Sheehan DV, Raj AB, Sheehan KH. Is buspirone effective for panic disorder? J Clin Psychopharmacol 1990;10:3-11.
11. Sheehan DV, Raj AB, Harnett-Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993;88:1-11.
12. Fulton B, Brogden RN. Buspirone an update review of its clinical pharmacology and therapeutic applications. CNS Drugs 1997;7: 68-88.
13. 1 receptor subtypes in the brain of control or 5,7-dihydroxytryptamine-treated rats. J Neurosci 1986;6:3474-82.
14. 1B agonists: a comparative study with dorsal raphe neurons. Neuropharmacology 1988;27:707-15.
15. Andrews N, File SE. Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence. Psychopharmacology (Berl) 1993;267:58-71.
16. Eison M. Serotonin a common neurobiological substrate in anxiety and depression. J Clin Psychopharmacol 1990;10:268-308.
17. VanderMaelen CP, Matheson GK, Wilderman RC, Patterson LA. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a nonbenzodiazepine anxiolytic drug. Eur J Pharmacol 1986;129:123-30.
18. 1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol 1989; 96:283-90.
19. 1A pre-synaptic but not postsynaptic receptor-mediated responses: relationship to antidepressant-like action. Eur J Pharmacol 1987;138:53-60.
20. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7[suppl]:24S-35S.
21. Blier P, De Montigny C. Differential effect of gepirone on presynaptic and postsynaptic serotonin receptors: single cell recording studies. J Clin Psychopharmacol 1990;10[suppl 3]:13S-20S.
22. 1A autoreceptors by chronic administration of 8-OH-DPAT. Neuropharmacology 1992; 31:1073-6.
23. Cowen PJ. Serotonin receptor subtypes: implications for psychopharmacology. Br J Psychiatry 1991;159[suppl 12]:7-14.
24. Robinson DS, Alms DR, Shrotriya RC. Serotonergic anxiolytics and treatment of depression. Psychopathology 1989;22[suppl 1] :27-36.
25. 2 receptor binding sites. Drug Dev Res 1991; 24:93-105.
26. Bergstrom RF, Lemberger L, Fand NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988;153[suppl 3]:47-50.
27. 1-adrenoceptors on rabbit aorta. Eur J Pharmacol 1993;24:141-8.
28. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monogr 1994;12:3-19.
29. 1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990;10[suppl 3]:67S-76S.
30. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996;32:335-42.
31. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991;36:749-50.
32. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-20.
33. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54:269-71.
34. Stembach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705-13.
35. Baetz M, Malcolm D. Serotonin syndrome from fluvoxamine and buspirone. Can J Psychiatry 1995;40:428-9.
36. Jenkins SC, Hansen MR. A pocket reference fo psychiatrists. 2nd ed. Washington, DC: American Psychiatric Press, 1995.
37. Rosenqvist M, Bergfeldt L, Aili H, Mathe AA. Sinus mode dysfunction during long-term lithium treatment. Br Heart J 1993;70: 371-5.
38. Gash AJ, Chhabra S, Eccleston D. Lithium augmentation in a case of renal impairment: risks vs. benefit. J Affect Dis 1993; 34:51-3.
39. Kaplan H, Sadock B. Pocket handbook of psychiatric drug treatment. 2nd Ed. Baltimore: Williams & Wilkins, 1996.
40. Thase ME, Rush AJ. Treatment resistant depression. In: Bloom F, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1081-97.